Fourth quarter 2021 (1 October – 31 December)

• Net sales was KDKK 0 (0)
• Operating profit (EBIT) was -2,721 (-493)
• Result per share (DKK) was -0.07 (-460,000)*
• Equity ratio was 0.89 (-0.42)

Full year 2020 (1 January – 31 December)

• Net sales was KDKK 0 (0)
• Operating profit (EBIT) was -5,870 (-627)
• Result per share (DKK) was -0,48 (-500,000)*
• Equity ratio was 0.89 (-0.42)

Result per share = result for the period / average number of shares
Equity ratio = Equity / Total assets
Number of shares on the 31/12/2020: 20,730,800
Number of shares on the 31/12/19: 1
Comparative figures are affected by the major changes in the number of shares during 2020

Highlights during the period (Q4, 2020):

DanCann Pharma A/S: The United Nations’ commission reclassifies cannabis, no longer considered risky narcotic FRI, DEC 04, 2020

DanCann Pharma A/S announced that The United Nations (UN) removed cannabis from list of most dangerous drugs following a recommendation from the World Health Organization (WHO), the United Nations’ Commission for Narcotic Drugs voted to remove cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs, a decision that is expected to eventually have a far-reaching impact on cannabis and cannabinoid research and for medical use and purposes worldwide.

DanCann Pharma A/S enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland) TUE, DEC 15, 2020

DanCann Pharma A/S announced that the Company has entered into an agreement with Cannassure Therapeutics Ltd. (TASE: CSURE) to be the exclusive multinational distributor of the Israelian-based company’s product portfolio for whole Scandinavia.

DanCann Pharma A/S submits new Application to the Danish Medicine Agency for authorisation to produce cannabis intermediate products THU, DEC 17, 2020

DanCann Pharma A/S announced that it has submitted a new Application to the Danish Medicine Agency (DMA) for approval for authorisation to produce cannabis intermediate products.

Highlights after the period (Q1, 2021):

DanCann Pharma’s strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor’s AKVANO® technology MON, JAN 18, 2021

DanCann Pharma A/S announced that its strategic partner, Cannassure Therapeutics Ltd. (TASE: CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products, has signed an exclusive licensing agreement with Lipidor AB (Nasdaq First North: LIPI). Under the agreement, Cannassure has the exclusive right to use Lipidor's proprietary drug delivery technology AKVANO® in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain, and lesions. DanCann Pharma is the exclusive multinational distributor of the Israelian-based company’s product portfolio for whole Scandinavia and Finland.

DanCann Pharma A/S announced the signing of a Letter of Intent with Canadian Tetra Bio-Pharma Inc. for the exclusive distribution of Reduvo™ Adversa® and Qixleef™ in Scandinavia and Germany THU, FEB 25, 2021

DanCann Pharma A/S announced the signing of a Letter of Intent with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa® and Qixleef™ in Denmark, Norway, Sweden, Finland, and Germany.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com